Inhaled insulin: new technology, new possibilities

S Bellary; A H Barnett

doi:10.1111/j.1742-1241.2006.00976.x

Inhaled insulin: new technology, new possibilities

Research output: Contribution to journal › Review article › peer-review

Abstract

The prevalence of diabetes is reaching epidemic proportions with an increasing need for new therapies. Several new therapies are in development and amongst these is inhaled insulin. Inhaled insulin is a novel way of delivering insulin and has been shown to have an efficacy comparable to subcutaneous insulin in patients with both type 1 and type 2 diabetes. Several inhaled insulin delivery systems are currently in development and the first of these, Exubera has recently been granted license in Europe and in the USA. In this article we review the efficacy and safety profile of Exubera and discuss its potential place in the management of diabetes.

Original language	English
Pages (from-to)	728-34
Number of pages	7
Journal	International Journal of Clinical Practice
Volume	60
Issue number	6
DOIs	https://doi.org/10.1111/j.1742-1241.2006.00976.x
Publication status	Published - Jun 2006

Keywords

Administration, Cutaneous
Administration, Inhalation
Administration, Oral
Diabetes Mellitus
Drug Costs
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Lung Diseases
Patient Satisfaction
Randomized Controlled Trials as Topic
Respiratory Function Tests
Treatment Outcome
Weight Gain
Journal Article
Review

Access to Document

10.1111/j.1742-1241.2006.00976.x

Cite this

@article{2e2eab0cdaf44a32aa974e5e5904a228,

title = "Inhaled insulin: new technology, new possibilities",

abstract = "The prevalence of diabetes is reaching epidemic proportions with an increasing need for new therapies. Several new therapies are in development and amongst these is inhaled insulin. Inhaled insulin is a novel way of delivering insulin and has been shown to have an efficacy comparable to subcutaneous insulin in patients with both type 1 and type 2 diabetes. Several inhaled insulin delivery systems are currently in development and the first of these, Exubera has recently been granted license in Europe and in the USA. In this article we review the efficacy and safety profile of Exubera and discuss its potential place in the management of diabetes.",

keywords = "Administration, Cutaneous, Administration, Inhalation, Administration, Oral, Diabetes Mellitus, Drug Costs, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Lung Diseases, Patient Satisfaction, Randomized Controlled Trials as Topic, Respiratory Function Tests, Treatment Outcome, Weight Gain, Journal Article, Review",

author = "S Bellary and Barnett, {A H}",

year = "2006",

month = jun,

doi = "10.1111/j.1742-1241.2006.00976.x",

language = "English",

volume = "60",

pages = "728--34",

journal = "International Journal of Clinical Practice",

issn = "1368-5031",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Inhaled insulin

T2 - new technology, new possibilities

AU - Bellary, S

AU - Barnett, A H

PY - 2006/6

Y1 - 2006/6

N2 - The prevalence of diabetes is reaching epidemic proportions with an increasing need for new therapies. Several new therapies are in development and amongst these is inhaled insulin. Inhaled insulin is a novel way of delivering insulin and has been shown to have an efficacy comparable to subcutaneous insulin in patients with both type 1 and type 2 diabetes. Several inhaled insulin delivery systems are currently in development and the first of these, Exubera has recently been granted license in Europe and in the USA. In this article we review the efficacy and safety profile of Exubera and discuss its potential place in the management of diabetes.

AB - The prevalence of diabetes is reaching epidemic proportions with an increasing need for new therapies. Several new therapies are in development and amongst these is inhaled insulin. Inhaled insulin is a novel way of delivering insulin and has been shown to have an efficacy comparable to subcutaneous insulin in patients with both type 1 and type 2 diabetes. Several inhaled insulin delivery systems are currently in development and the first of these, Exubera has recently been granted license in Europe and in the USA. In this article we review the efficacy and safety profile of Exubera and discuss its potential place in the management of diabetes.

KW - Administration, Cutaneous

KW - Administration, Inhalation

KW - Administration, Oral

KW - Diabetes Mellitus

KW - Drug Costs

KW - Humans

KW - Hypoglycemia

KW - Hypoglycemic Agents

KW - Insulin

KW - Lung Diseases

KW - Patient Satisfaction

KW - Randomized Controlled Trials as Topic

KW - Respiratory Function Tests

KW - Treatment Outcome

KW - Weight Gain

KW - Journal Article

KW - Review

UR - https://onlinelibrary.wiley.com/doi/full/10.1111/j.1742-1241.2006.00976.x

U2 - 10.1111/j.1742-1241.2006.00976.x

DO - 10.1111/j.1742-1241.2006.00976.x

M3 - Review article

C2 - 16805759

SN - 1368-5031

VL - 60

SP - 728

EP - 734

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

IS - 6

ER -

Inhaled insulin: new technology, new possibilities

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this